<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16">
 <label>16</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Xu</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Jia</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Yue</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Chang</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>R</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Anti-PD-1 Antibody SHR-1210 Combined With Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study</article-title>. 
  <source>Clin Cancer Res</source> (
  <year>2019</year>) 
  <volume>25</volume>(
  <issue>2</issue>):
  <page-range>515â€“23</page-range>. 
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2484</pub-id>
 </mixed-citation>
</ref>
